Ken Griffin Aquestive Therapeutics, Inc. Call Options Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
Call Options
11 transactions
Others Institutions Holding AQST
# of Institutions
125Shares Held
47.4MCall Options Held
64.2KPut Options Held
204K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$37.1 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$20.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.33MShares$16.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.98MShares$11.3 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.19MShares$8.28 Million0.32% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $202M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...